《中国糖尿病杂志》官方网站

20

您的位置:首页 > 中国糖尿病杂志 > 2012年 > 9期

最终结果:Ghrelin可抑制人体胰岛素分泌,这是其临床意义吗?

来自:中国糖尿病资讯网  编辑:editor|点击数:|2012-10-17

  【提要】Ghrelin是在人体和大鼠的胃内发现的28-氨基酸肽,是生长激素促分泌素受体(GHS-R1a)的内源性配体。1999年首次被发现。其作用包括:与GHS-R1a结合,增加脑下垂体分泌生长激素;影响食物摄入和体脂水平;调节细胞增殖和存活、生长和繁殖以及代谢等。最近,Ghrelin是否会对β细胞功能产生作用也成为研究热点之一。这一领域的研究具有重要意义,其可能增加胰岛素分泌从而可能成为治疗T2DM的新途径。

  【关键词】Ghrelin;糖尿病,2型;胰岛素

  Final answer: Ghrelin can suppress insulin secretion in humans, but Is It Clinically Relevant? HONG Shan-shan,QIAN Rong-li. Editorial Department of Chinese Journal of Diabetes, Beijing 100034, China

  【Summary】Ghrelin is a 28–amino acid peptide initially isolated from rat and human stomachs as an endogenous ligand for the growth hormone secretagogue receptor type 1a (GHS-R1a) and was discovered in 1999, ghrelin was known to increase growth hormone release from the pituitary gland by binding to GHS-R1a, had a role in food intake and body adiposity, and regulated cell proliferation and survival, apoptosis, inflammation, angiogenesis, development and reproduction as well as metabolism. Recently, it has become of great research interest whether ghrelin also has a role in β-cell function. This research area is particularly important given its potential to lead to the development of novel strategies to increase insulin secretion for the treatment of type 2 diabetes. Here we translated the essentials of “Final answer: Ghrelin can suppress insulin secretion in humans, but is it clinically relevant? (Diabetes, 2010, 59:2726-2728)”in the following article.

  【Key Words】Ghrelin;Diabetes mellitus,type 2;Insulin

上一篇:Vaspin与肥胖及2型糖尿病相关性研究进展 下一篇:脂肪生成的转录调控——迈向代谢性疾病治疗的新时代